- Collagen Matrix Acquires Polyganics 5 October 2022 - Oakland, N.J., Groningen, The Netherlands, October 5, 2022 – Collagen Matrix, Inc. (“Collagen Matrix”), a global leader in regenerative medicine and a Linden Capital Partners (“Linden”) portfolio company, today announced the acquisition of Polyganics, B.V (“Polyganics”). Polyganics is a medical technology company that develops and manufactures bioresorbable medical devices. The acquisition expands Collagen Matrix’s portfolio… read more
- First Patient Treated in Polyganics’ ENCASE II Trial for Innovative Dura Sealant Patch, LIQOSEAL 21 May 2021 - Randomized controlled trial in the US and Europe will enable LIQOSEAL to be submitted for FDA approval Groningen, The Netherlands, May 21 2021 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patient in its ENCASE II clinical trial for LIQOSEAL. LIQOSEAL is an easy-to-use,… read more
- Polyganics Opens New State-of-the-Art Facility to Drive Growth 20 April 2021 - Groningen, The Netherlands, 20 April 2021 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announces its move to a state-of-the art, purpose-built facility on the Zernike Campus, Groningen. The new building will house Polyganics’ research laboratories, manufacturing and packaging facilities, and its offices. The expansion is essential to accommodate… read more
- First Patients Treated in First-in-Human Trial for ACTISEAL® – Polyganics’ Innovative Liver and Pancreas Sealant Patch 15 September 2020 - Groningen, The Netherlands, 15 September 2020 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patients in its first-in-human study for ACTISEAL®, its Liver and Pancreas Sealant Patch. The ‘SHIELDS’ trial is a prospective, multicenter study, evaluating the safety and performance of ACTISEAL® in reducing… read more
- Polyganics Awarded €1.2 Million for Clinical Development of Liver and Pancreas Sealant Patch 13 May 2020 - Groningen, The Netherlands, 13 May 2020 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has received EUR 1.2 million in funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN) and the city and province of Groningen, to support clinical validation… read more
- Polyganics Announces Start Building New Facility 3 March 2020 - Groningen, The Netherlands, 3 March 2020 - Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced the ground-breaking of a new facility at the Zernike Campus, Groningen. Polyganics aims to move into its new facility, which will house its headquarters, state-of-the-art research laboratories and expanded manufacturing and packaging facilities, in 2021.… read more
- Polyganics Achieves CE Mark Certification for LIQOSEAL® 7 January 2020 - Groningen, The Netherlands, 07 January 2020 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has obtained CE marking for LIQOSEAL®, its easy-to-use and innovative dural sealant patch, and will launch the device in Europe with immediate effect. Approval of the CE mark is based on outstanding… read more
- Polyganics Achieves Positive 3-month Follow-up Data of ENCASE I, the First Clinical Trial for LIQOSEAL® 17 September 2019 - Groningen, The Netherlands, 17 September 2019 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, has today announced positive data from its ENCASE I* clinical trial. The ENCASE I trial is focused on the evaluation of the safety and performance of LIQOSEAL® in reducing cerebrospinal fluid (CSF) leakage following elective cranial… read more
- Polyganics Builds New Facility to Continue Growth, Supported by RIG Subsidy of €3.8 Million 10 April 2019 - Groningen, The Netherlands, 10 April 2019 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, is expanding its capacity with a new facility at the Zernike Campus, Groningen, to enter a new phase of commercial and R&D growth. Polyganics has been awarded a subsidy of €3.8 million by the Regional Investment… read more
- Polyganics Initiates First-in-Human Trial of LIQOSEAL®, its Innovative Approach for Dural Closure 22 October 2018 - Groningen, The Netherlands, 22 October 2018 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced that it has initiated enrollment of patients into a first-in-human clinical trial of LIQOSEAL®, its dura sealant patch. The self-adhesive patch has been developed to reduce cerebrospinal fluid (CSF) leakage following brain surgery The… read more
- Polyganics Strengthens Global Distribution Network with Appointment of Synovis MCA as US-wide Distributor of NEUROCAP® 10 September 2018 - Groningen, The Netherlands – 10 September 2018 – Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices, today announced that it has signed an agreement with Synovis Micro Companies Alliance Inc. (“Synovis MCA”), a subsidiary of Baxter International Inc., to be the exclusive distributor of its nerve capping device,… read more
- FDA Grants Breakthrough Device Designation to Polyganics’ Liver and Pancreas Sealant Patch 9 March 2018 - Groningen, The Netherlands, 8 March 2018 – Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices, today announced that the US Food and Drug Administration (FDA) has granted Polyganics’ request for Breakthrough Device designation to its Liver and Pancreas Sealant Patch. The Liver and Pancreas Sealant patch is considered… read more
- Polyganics awarded €1.2 million to complete clinical development of dura sealant patch 1 December 2017 - First-in-human clinical studies of the device expected to begin in early 2018 Groningen, The Netherlands, 1 December 2017 – Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices, today announced it has been awarded funding from the European Fund for Regional Development (ERDF) by the European Union, to support… read more
- Polyganics Extends Global Distribution Network with the Addition of Multiple US Distributors 5 September 2017 - Groningen, The Netherlands, 5 September 2017 – Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices to promote peripheral nerve reconstruction and regeneration, announces the appointment of six US distributors for its peripheral nerve repair (PNR) portfolio. New agreements with Southern Orthopaedics, Medex Surgical, Rascher Medical Solutions, Med Rep… read more
- Polyganics signs up multiple distributors in Europe to accelerate roll-out of Peripheral Nerve Repair portfolio 8 June 2017 - Groningen, The Netherlands, 8 June 2017 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it has signed agreements with leading medical technology distributors in Europe, to meet the growing distribution demands for Polyganics’ Peripheral Nerve Repair (PNR)… read more
- Polyganics Announces Enrollment of the First Patient in its PROTECT NEURO Study 20 April 2017 - Groningen, The Netherlands, 20 April 2017 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it has enrolled the first patient in its international PROTECT NEURO study to treat and prevent symptomatic neuroma. The first patient was treated… read more
- Polyganics’ “STOP NEUROMA” Study Interim Data Shows Reduction in Pain 16 February 2017 - NEUROCAP® 3-month interim data show an average pain reduction of 84% Final patient recruited in “STOP NEUROMA” clinical study, full data due to be reported by Q3 2018. Groningen, The Netherlands 16 February 2017 – Polyganics, a privately held medical technology company, announced today that interim results show a sharp improvement in pain reduction observed across… read more
- Polyganics announces Birmingham Hand Centre efficacy study of nerve conduit NEUROLAC® in finger surgery 7 December 2016 - NEUROLAC® nerve conduit to be evaluated in 170+ patient CONNECT study over 36 months, with interim results due in Q4 2017 and full results in H2 2019 Study centre – the Birmingham Hand Centre, part of the NHS’s Queen Elizabeth Hospital in Birmingham, a leading UK centre in hand and reconstructive surgery Groningen, The Netherlands,… read more
- Polyganics Announces CE Mark for NEUROCAP®, the Nerve Capping Device for Treatment and Prevention of Symptomatic Neuroma 21 June 2016 - Groningen, The Netherlands, 21 June 2016 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it has received the CE mark for NEUROCAP®, its nerve capping device. Polyganics intends to launch NEUROCAP® in several European countries later this year.… read more
- Polyganics Announces Enrollment of First Patients in Multicenter Study for NEUROCAP® Nerve Capping Device 10 May 2016 - Groningen, The Netherlands, 9 May 2016, Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that the first four patients have been enrolled in the “STOP NEUROMA” study. The STOP NEUROMA study (Surgical Treatment Of symPtomatic Neuroma) will examine the… read more
- Polyganics appoints Dr Jan Öhrström to Supervisory Board 15 March 2016 - Groningen, The Netherlands, 15 March 2016 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve repair, neurosurgery, general surgery, as well as ear, nose & throat surgery, today announced it has appointed Dr Jan K. Öhrström to its Supervisory Board. The appointment is effective… read more
- Polyganics Receives Chinese Food and Drug Administration (CFDA) Approval for NEUROLAC® 26 February 2016 - Beijing, China, 26 February 2016 – Polyganics today announced it has received Chinese FDA (CFDA) clearance for NEUROLAC®, a unique synthetic and resorbable nerve conduit designed to support regeneration of peripheral nerve discontinuities up to 20 mm in patients who have sustained a complete division of a nerve. Rudy Mareel, CEO a.i.: “NEUROLAC® offers a… read more
- Polyganics Receives FDA 510(k) Clearance for Nerve Capping Device NEUROCAP® 26 January 2016 - Groningen, The Netherlands, 26 January 2016 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve repair, neurosurgery, general surgery, as well as ear, nose & throat surgery, today announced it has received FDA 510(k) clearance for NEUROCAP, an innovative device designed to reduce painful… read more
- Polyganics and MicroAire sign exclusive distribution agreement for peripheral nerve repair portfolio in the US, Canada and Puerto Rico 21 January 2016 - Groningen, The Netherlands, 21 January 2016 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve repair, neurosurgery, general surgery, as well as ear, nose & throat surgery, today announced it has signed an exclusive distribution agreement with its strategic partner MicroAire Surgical Instruments LLC… read more
- Polyganics announces divestment of its ENT activities 7 November 2014 - Groningen, the Netherlands, 7 November 2014 – Polyganics today announces it has signed an agreement to sell its activities in the field of Ear, Nose and Throat (ENT) surgery to Stryker. The ENT activities comprise a portfolio of sinunasal and otological dressings, including the marketed products NASOPORE®, HEMOPORE®, OTOPORE® and NASOPORE-FD®. As part of the… read more
- Polyganics obtains FDA 510k clearance to market HEMOPORE® 23 October 2014 - Groningen, the Netherlands, 23 October 2014 – Today, Polyganics announces it has obtained FDA clearance for HEMOPORE®. HEMOPORE® offers two forms of post-op hemostatic control in one bioresorbable sinunasal dressing. The clearance comes after the CE regulatory approval of NASOPORE FD® in April 2014 and FDA 510k approval of NASOPORE FD® in October 2014. “This… read more
- Polyganics obtains FDA 510k clearance to market NASOPORE-FD® 7 August 2014 - Groningen, the Netherlands, 7 August 2014 – Today, Polyganics announces it has obtained FDA clearance for NASOPORE-FD®, a sinunasal dressing with a rapid clearance time. The approval comes after the CE regulatory approval of NASOPORE-FD® in April 2014 and marks a next step in the commercialization Polyganics’ front-running bioresorbable nasal dressing portfolio marketed under the… read more
- Polyganics obtains CE approval to market NASOPORE-FD® 17 April 2014 - Groningen, the Netherlands, 17 April 2014 – Polyganics today announces the CE regulatory approval of NASOPORE- FD®, a sinunasal dressing with a rapid clearance time. NASOPORE-FD® is the latest addition to Polyganics’ front-running bioresorbable nasal dressing portfolio marketed under the NASOPORE® brand. After insertion, NASOPORE-FD® exerts moderate elastic compression on the surrounding tissue for 36-48… read more
- Polyganics wins High Growth Award 2012 29 November 2012 - Groningen, the Netherlands, 29 November 2012 – Today, Polyganics announces it has won the High Growth Award 2012. The High Growth Award is a prize for Dutch companies that combine growth, both in quality and quantity, with a clear vision of the future. Polyganics effectively proves that entrepreneurship and innovation continue to bear fruit, also… read more
